{"transactions":[{"id":939999,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":69436,"kind":"person","name":"Martin James Joseph","position":1,"cik":"0001510224","reported_name":"Martin James Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-CEO and CFO"}}],"security":"Stock Options (Right to Buy)","published_at":"2026-01-13T21:10:06.000Z","date":"2026-01-09","kind":"grant","planned":false,"acquired":true,"shares":49229,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Compensation Committee of the Board of Directors. The non-qualified stock options are granted under the Issuer's 2025 Equity Incentive Plan and the exercisability shall be subject to execution of the Issuer's form of Non-Qualified Stock Option Agreement. The non-qualified stock options shall vest as follows: one-half shall vest and become exercisable on January 9, 2027 and the remaining half shall vest and become exercisable in eight equal quarterly installments commencing on March 31, 2027, subject to the Reporting Person continuing to serve as an officer of the Issuer on each applicable vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Compensation Committee of the Board of Directors. The non-qualified stock options are granted under the Issuer's 2025 Equity Incentive Plan and the exercisability shall be subject to execution of the Issuer's form of Non-Qualified Stock Option Agreement. The non-qualified stock options shall vest as follows: one-half shall vest and become exercisable on January 9, 2027 and the remaining half shall vest and become exercisable in eight equal quarterly installments commencing on March 31, 2027, subject to the Reporting Person continuing to serve as an officer of the Issuer on each applicable vesting date."}],"balance_after":49229,"derivative":{"exercise_price":1.1,"expiration_date":"2036-01-09","underlying":"Common Stock","underlying_shares":49229},"source":{"system":"sec-edgar","filing":"0001493152-26-002036","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315226002036/ownership.xml","form_type":"4"}},{"id":1011279,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":69436,"kind":"person","name":"Martin James Joseph","position":1,"cik":"0001510224","reported_name":"Martin James Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-CEO and CFO"}}],"security":"Warrants","published_at":"2025-10-30T20:15:20.000Z","date":"2025-10-28","kind":"grant","planned":false,"acquired":true,"shares":7196,"price":1.39,"value":10002.44,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Reporting Person purchased units at $1.39 per unit with each unit consisting of one share of common stock and a warrant to purchase two shares of common stock. The shares of common stock and warrants purchased are exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 thereunder, as it was approved by a Special Committee of the Board of Directors of the Issuer, which Special Committee consisted of two non-employee directors. The warrants were exercisable upon issuance."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Reporting Person purchased units at $1.39 per unit with each unit consisting of one share of common stock and a warrant to purchase two shares of common stock. The shares of common stock and warrants purchased are exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 thereunder, as it was approved by a Special Committee of the Board of Directors of the Issuer, which Special Committee consisted of two non-employee directors. The warrants were exercisable upon issuance."}],"balance_after":7196,"derivative":{"exercise_price":1.24,"expiration_date":"2028-01-28","underlying":"Common Stock","underlying_shares":7196},"source":{"system":"sec-edgar","filing":"0001493152-25-020218","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315225020218/ownership.xml","form_type":"4"}},{"id":1011278,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":69436,"kind":"person","name":"Martin James Joseph","position":1,"cik":"0001510224","reported_name":"Martin James Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-CEO and CFO"}}],"security":"Common Stock","published_at":"2025-10-30T20:15:20.000Z","date":"2025-10-28","kind":"grant","planned":false,"acquired":true,"shares":3598,"price":1.39,"value":5001.22,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Reporting Person purchased units at $1.39 per unit with each unit consisting of one share of common stock and a warrant to purchase two shares of common stock. The shares of common stock and warrants purchased are exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 thereunder, as it was approved by a Special Committee of the Board of Directors of the Issuer, which Special Committee consisted of two non-employee directors. The warrants were exercisable upon issuance."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes shares of common stock issuable upon vesting of restricted stock units."}],"balance_after":44167,"source":{"system":"sec-edgar","filing":"0001493152-25-020218","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315225020218/ownership.xml","form_type":"4"}},{"id":1387506,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":69436,"kind":"person","name":"Martin James Joseph","position":1,"cik":"0001510224","reported_name":"Martin James Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-CEO and CFO"}}],"security":"Common Stock","published_at":"2024-10-11T20:05:54.000Z","date":"2024-10-09","kind":"grant","planned":false,"acquired":true,"shares":40000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The grant is exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 thereunder, as it was approved by the Board of Directors of the Issuer. One half of the RSUs are fully vested, with the balance vesting in eight equal quarterly installments on the last day of each quarter commencing with the quarter ending September 30, 2025, subject to continued services for the Company as of each applicable vesting date. Shares of common stock will be delivered to the Reporting Person promptly upon vesting, unless the Reporting Person elects to defer delivery. The RSUs were granted under the Issuer's 2015 Equity Incentive Plan and will vest in full upon a Change of Control as defined in such Plan."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The grant is exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 thereunder, as it was approved by the Board of Directors of the Issuer. One half of the RSUs are fully vested, with the balance vesting in eight equal quarterly installments on the last day of each quarter commencing with the quarter ending September 30, 2025, subject to continued services for the Company as of each applicable vesting date. Shares of common stock will be delivered to the Reporting Person promptly upon vesting, unless the Reporting Person elects to defer delivery. The RSUs were granted under the Issuer's 2015 Equity Incentive Plan and will vest in full upon a Change of Control as defined in such Plan."}],"balance_after":40569,"source":{"system":"sec-edgar","filing":"0001493152-24-040900","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315224040900/ownership.xml","form_type":"4"}},{"id":1825672,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":69436,"kind":"person","name":"Martin James Joseph","position":1,"cik":"0001510224","reported_name":"Martin James Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-CEO and CFO"}}],"security":"Stock Options (Right to Buy)","published_at":"2023-07-20T20:05:28.000Z","date":"2023-07-18","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The stock options were issued pursuant to the 2015 Equity Incentive Plan and are intended to be incentive stock options within the meaning of Section 422 of the Internal Revenue Code (the \"Code\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options vest and become exercisable as follows, subject in each case to the limitations on exercisability of incentive stock options under Section 422 of the Code: one-half will vest on July 18, 2024 and the remaining half will vest in eight equal quarterly installments on the last day of March, June, September, and December commencing on September 30, 2024, subject to continued employment on each applicable vesting date."}],"balance_after":30000,"derivative":{"exercise_price":2.67,"expiration_date":"2033-07-18","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001493152-23-025084","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315223025084/ownership.xml","form_type":"4"}},{"id":2195557,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":69436,"kind":"person","name":"Martin James Joseph","position":1,"cik":"0001510224","reported_name":"Martin James Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co- Interim CEO and CFO"}}],"security":"Stock Options (Right to Buy)","published_at":"2022-08-03T20:03:10.000Z","date":"2022-07-25","kind":"grant","acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The stock options were issued pursuant to the 2015 Equity Incentive Plan and are intended to be incentive stock options within the meaning of Section 422 of the Internal Revenue Code (the \"Code\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options vest and become exercisable as follows, subject in each case to the limitations on exercisability of incentive stock options under Section 422 of the Code: one-half will vest on July 25, 2023 and the remaining half will vest in eight equal quarterly installments on the last day of March, June, September, and December commencing on September 30, 2023, subject to continued employment on each applicable vesting date."}],"balance_after":300000,"derivative":{"exercise_price":0.42,"expiration_date":"2032-07-25","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001493152-22-021150","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315222021150/ownership.xml","form_type":"4"}},{"id":2629138,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":69436,"kind":"person","name":"Martin James Joseph","position":1,"cik":"0001510224","reported_name":"Martin James Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options (Right to Buy)","published_at":"2021-07-20T20:06:00.000Z","date":"2021-07-16","kind":"grant","acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The stock options were issued pursuant to the 2015 Equity Incentive Plan and are intended to be incentive stock options within the meaning of Section 422 of the Internal Revenue Code (the \"Code\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options vest and become exercisable as follows, subject in each case to the limitations on exercisability of incentive stock options under Section 422 of the Code: one-half will vest on July 16, 2022 and the remaining half will vest in eight equal quarterly installments on the last day of March, June, September, and December commencing on September 30, 2022, subject to continued employment on each applicable vesting date."}],"balance_after":250000,"derivative":{"exercise_price":1.11,"expiration_date":"2031-07-16","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001493152-21-017327","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315221017327/ownership.xml","form_type":"4"}},{"id":2694727,"issuer":{"id":7591,"kind":"organization","name":"PetVivo Holdings, Inc.","symbol":"PETV"},"owners":[{"id":69436,"kind":"person","name":"Martin James Joseph","position":1,"cik":"0001510224","reported_name":"Martin James Joseph","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-26T16:04:28.000Z","date":"2021-04-24","kind":"purchase","acquired":true,"shares":3000,"price":7,"value":21000.0,"ownership":{"direct":true},"balance_after":67384,"source":{"system":"sec-edgar","filing":"0001493152-21-012958","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1510224/000149315221012958/ownership.xml","form_type":"4"}},{"id":2756941,"issuer":{"id":7591,"kind":"organization","name":"PetVivo Holdings, Inc.","symbol":"PETV"},"owners":[{"id":69436,"kind":"person","name":"Martin James Joseph","position":1,"cik":"0001510224","reported_name":"Martin James Joseph","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Warrant","published_at":"2021-04-05T15:43:35.000Z","date":"2021-03-12","kind":"other","acquired":false,"shares":1117,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":22500,"derivative":{"exercise_price":1.6,"exercise_date":"2020-06-30","expiration_date":"2025-06-30","underlying":"Common Stock","underlying_shares":1117},"source":{"system":"sec-edgar","filing":"0001493152-21-007962","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1510224/000149315221007962/ownership.xml","form_type":"4"}},{"id":2756940,"issuer":{"id":7591,"kind":"organization","name":"PetVivo Holdings, Inc.","symbol":"PETV"},"owners":[{"id":69436,"kind":"person","name":"Martin James Joseph","position":1,"cik":"0001510224","reported_name":"Martin James Joseph","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Warrant","published_at":"2021-04-05T15:43:35.000Z","date":"2021-03-12","kind":"other","acquired":false,"shares":1227,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":23617,"derivative":{"exercise_price":1.27,"exercise_date":"2020-03-31","expiration_date":"2025-03-31","underlying":"Common Stock","underlying_shares":1227},"source":{"system":"sec-edgar","filing":"0001493152-21-007962","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1510224/000149315221007962/ownership.xml","form_type":"4"}},{"id":2756939,"issuer":{"id":7591,"kind":"organization","name":"PetVivo Holdings, Inc.","symbol":"PETV"},"owners":[{"id":69436,"kind":"person","name":"Martin James Joseph","position":1,"cik":"0001510224","reported_name":"Martin James Joseph","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Warrant","published_at":"2021-04-05T15:43:35.000Z","date":"2021-03-12","kind":"other","acquired":false,"shares":1103,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":24844,"derivative":{"exercise_price":1.95,"exercise_date":"2019-12-31","expiration_date":"2024-12-31","underlying":"Common Stock","underlying_shares":1103},"source":{"system":"sec-edgar","filing":"0001493152-21-007962","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1510224/000149315221007962/ownership.xml","form_type":"4"}},{"id":2756938,"issuer":{"id":7591,"kind":"organization","name":"PetVivo Holdings, Inc.","symbol":"PETV"},"owners":[{"id":69436,"kind":"person","name":"Martin James Joseph","position":1,"cik":"0001510224","reported_name":"Martin James Joseph","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-05T15:43:35.000Z","date":"2021-03-12","kind":"other","acquired":true,"shares":3447,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":64384,"source":{"system":"sec-edgar","filing":"0001493152-21-007962","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1510224/000149315221007962/ownership.xml","form_type":"4"}},{"id":3100774,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":69436,"kind":"person","name":"Martin James Joseph","position":1,"cik":"0001510224","reported_name":"Martin James Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options (Right to Buy)","published_at":"2020-06-24T20:05:37.000Z","date":"2020-06-22","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The stock options are intended to be incentive stock options within the meaning of Section 422 of the Internal Revenue Code."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options vest as follows: 75,000 stock options will vest on the one year anniversary of the grant date and the remaining 75,000 stock options will vest in eight equal quarterly increments with the first such quarterly increment vesting on September 30, 2021."}],"balance_after":150000,"derivative":{"exercise_price":1.33,"expiration_date":"2030-06-22","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001493152-20-011718","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315220011718/ownership.xml","form_type":"4"}},{"id":3808998,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":69436,"kind":"person","name":"Martin James Joseph","position":1,"cik":"0001510224","reported_name":"Martin James Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options (Right to Buy)","published_at":"2018-09-24T13:00:31.000Z","date":"2018-09-21","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The stock options vest as follows: 1/4 will vest on the one year anniversary of the grant date and the remaining 3/4 will vest in 12 equal quarterly increments."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options are intended to be incentive stock options within the meaning of Section 422 of the Internal Revenue Code. Only $100,000 (or 35,971 options) may first become exercisable by the Reporting Person in each calendar year."}],"balance_after":150000,"derivative":{"exercise_price":2.78,"expiration_date":"2028-09-20","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001493152-18-013622","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315218013622/ownership.xml","form_type":"4"}}]}